Lungpacer Medical

Lungpacer Medical is a leader in neurostimulation technologies for critical care, dedicated to helping patients wean from mechanical ventilation through diaphragm pacing. Founded over 15 years ago (c. 2009), the company's AeroPace System — FDA Premarket Approved in 2024 — uses electrical stimulation of phrenic nerves to rebuild diaphragm strength and reduce ventilator dependency in adult ICU patients. The company received FDA Breakthrough Device designation in 2017 and Emergency Use Authorization during COVID-19. Headquartered in Vancouver, BC, Canada with U.S. offices in Exton, Pennsylvania.